{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:30:36Z","timestamp":1753893036990,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Hematol."],"abstract":"<jats:p>Clinical features of Waldenstr\u00f6m Macroglobulinemia (WM) are variable, often leading to heterogeneous decisions regarding patients\u2019 diagnosis, risk stratification, and treatment. This study assessed the agreement rates on WM diagnosis, risk stratification, and active treatment strategies to capture how this heterogeneity may influence national practices among hematologists. A two-round Delphi-like Panel with 22 national hematologists experienced in WM was conducted online, where 33 statements were classified using a 4-point Likert scale. For each statement, the consensus level was set at 70% for \u201cfully agree\/disagree\u201d; the majority level was defined as &amp;gt;70% in agreement or disagreement. After two rounds, no statements were categorized as consensus, and 15 out of 33 failed to obtain a qualified majority. Globally, the experts could not reach a qualified majority in approximately half of the sentences from each category (diagnosis, risk assessment, and therapeutic decision), indicating that contradictory opinions are transversal to all the topics involving WM. A lack of consensus in diagnosing and managing WM among Portuguese hematologists became evident. These results illustrate heterogeneity in clinical practices, and future research initiatives should be considered to improve and reinforce accepted guidelines for diagnosing, assessing, and treating WM patients.<\/jats:p>","DOI":"10.3389\/frhem.2023.1203369","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:27:12Z","timestamp":1687782432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Waldenstr\u00f6m Macroglobulinemia diagnosis, risk assessment and treatment in Portugal \u2013 results from a Delphi-like Panel"],"prefix":"10.3389","volume":"2","author":[{"given":"Rui","family":"Bergantim","sequence":"first","affiliation":[]},{"given":"S\u00e9rgio","family":"Chacim","sequence":"additional","affiliation":[]},{"given":"Alexandra","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Ana M.","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo M. C.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40320-5_16","article-title":"Waldenstrom macroglobulinemia: genomic aberrations and treatment","volume":"169","author":"Kapoor","year":"2016","journal-title":"Cancer Treat Res."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy146","article-title":"Waldenstrom\u2019s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Kastritis","year":"2018","journal-title":"Ann. Oncol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.365","article-title":"Toward personalized treatment in waldenstrom macroglobulinemia","volume":"2017","author":"Castillo","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in waldenstrom\u2019s macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.05.011","article-title":"Proteasome inhibitors in waldenstrom macroglobulinemia","volume":"32","author":"Kastritis","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30087-5","article-title":"Treatment and outcome patterns in European patients with waldenstr\u00f6m\u2019s macroglobulinaemia: a large, observational, retrospective chart review","volume":"5","author":"Buske","year":"2018","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12846","article-title":"The international prognostic scoring system for waldenstrom\u2019s macroglobulinemia is applicable in patients treated with rituximab-based regimens","volume":"93","author":"Dimopoulos","year":"2008","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077025","article-title":"Treatment of waldenstrom\u2019s macroglobulinemia with the combination of fludarabine and cyclophosphamide","volume":"44","author":"Dimopoulos","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S191179","article-title":"Rituximab-based combination therapy in patients with waldenstrom macroglobulinemia: a systematic review and meta-analysis","volume":"12","author":"Zheng","year":"2019","journal-title":"Onco Targets Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"Cd006719","DOI":"10.1002\/14651858.CD006719.pub3","article-title":"Alkylating agents for waldenstrom\u2019s macroglobulinaemia","volume":"1","author":"Yang","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.05.009","article-title":"Alkylating agents in the treatment of waldenstr\u00f6m macroglobulinemia","volume":"32","author":"Buske","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.28","article-title":"Waldenstrom macroglobulinemia: prognosis and management","volume":"5","author":"Oza","year":"2015","journal-title":"Blood Cancer J."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in waldenstr\u00f6m macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br. J. Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type waldenstr\u00f6m macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bjh.13361","article-title":"MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity","volume":"169","author":"Schmidt","year":"2015","journal-title":"Br. J. Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated waldenstrom\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.03.008","article-title":"The epidemiology of waldenstrom macroglobulinemia","volume":"60","author":"McMaster","year":"2023","journal-title":"Semin. Hematol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-hodgkin\u2019s lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med. Sci. (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15792","article-title":"Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88(L265P) detection in lymphomas with plasmacytic\/plasmacytoid differentiation","volume":"186","author":"Willenbacher","year":"2019","journal-title":"Br. J. Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01762-3","article-title":"Diagnostics in waldenstrom\u2019s macroglobulinemia: a consensus statement of the European consortium for waldenstrom\u2019s macroglobulinemia","volume":"37","author":"Dogliotti","year":"2022","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw072","article-title":"Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations","volume":"145","author":"King","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000725","article-title":"How I treat waldenstrom macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153714","article-title":"Real world experience on the use of ibrutinib monotherapy in waldenstr\u00f6m macroglobulinemia","volume":"138","author":"Ogunbiyi","year":"2021","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1938030","article-title":"Treatment and outcome patterns of patients with waldenstrom\u2019s macroglobulinemia: a large, multicenter retrospective review in China","volume":"62","author":"Cao","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18036","article-title":"Diagnosis and management of waldenstrom macroglobulinaemia-a British society for haematology guideline","volume":"197","author":"Pratt","year":"2022","journal-title":"Br. J. Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2018.004","article-title":"Waldenstrom\u2019s macroglobulinemia: an update","volume":"10","author":"Mazzucchelli","year":"2018","journal-title":"Mediterr J. Hematol. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.05.003","article-title":"Genomic landscape of waldenstrom macroglobulinemia","volume":"32","author":"Treon","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1822816","article-title":"Emerging drugs for the treatment of waldenstrom macroglobulinemia","volume":"25","author":"Despina","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-agent ibrutinib for rituximab-refractory waldenstrom macroglobulinemia: final analysis of the substudy of the phase III Innovate(TM) trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000363","article-title":"Response and survival outcomes to ibrutinib monotherapy for patients with waldenstrom macroglobulinemia on and off clinical trials","volume":"4","author":"Castillo","year":"2020","journal-title":"Hemasphere"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol."}],"container-title":["Frontiers in Hematology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhem.2023.1203369\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:27:15Z","timestamp":1687782435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhem.2023.1203369\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":38,"alternative-id":["10.3389\/frhem.2023.1203369"],"URL":"https:\/\/doi.org\/10.3389\/frhem.2023.1203369","relation":{},"ISSN":["2813-3935"],"issn-type":[{"type":"electronic","value":"2813-3935"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"article-number":"1203369"}}